Search

Your search keyword '"Falcone AP"' showing total 4 results
Start Over Author "Falcone AP" Journal leukemia lymphoma
4 results on '"Falcone AP"'

1. Real-world evidence on the use of daratumumab, bortezomib and dexamethasone (DVd) in lenalidomide-refractory myeloma patients: subgroup analysis of the multicenter retrospective experience by "rete ematologica pugliese".

Author

Mele G, Di Renzo N, Cascavilla N, Carella AM, Guarini A, Mazza P, Melillo L, Pavone V, Tarantini G, Curci P, Falcone AP, Germano C, Mele A, Merchionne F, Palazzo G, Palumbo G, Quinto AM, Reddiconto G, Rossini B, Spina A, Sgherza N, Specchia G, Musto P, and Pastore D

Subjects
Humans, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Bortezomib therapeutic use, Dexamethasone therapeutic use, Lenalidomide therapeutic use, Retrospective Studies, Multicenter Studies as Topic, Antibodies, Monoclonal, Multiple Myeloma drug therapy, Neoplasms, Plasma Cell
Published
2023
Full Text
View/download PDF

2. Real world Italian experience of pomalidomide plus low-dose dexamethasone in the relapsed and refractory myeloma setting: extended follow-up of a retrospective multicenter study by the 'Rete Ematologica Pugliese E Basilicata'.

Author

Mele G, Pastore D, Di Renzo N, Fragasso A, Guarini A, Mazza P, Musto P, Pavone V, Tarantini G, Curci P, Falcone AP, Mele A, Miccolis MR, Palazzo G, Palumbo G, Quinto AM, Reddiconto G, Rizzi R, Cascavilla N, Specchia G, and Capalbo SF

Subjects
Adult, Aged, Aged, 80 and over, Dexamethasone administration & dosage, Female, Follow-Up Studies, Humans, Italy, Male, Middle Aged, Multiple Myeloma pathology, Neoplasm Recurrence, Local pathology, Prognosis, Retrospective Studies, Survival Rate, Thalidomide administration & dosage, Thalidomide analogs & derivatives, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Drug Resistance, Neoplasm drug effects, Multiple Myeloma drug therapy, Neoplasm Recurrence, Local drug therapy, Salvage Therapy
Published
2019
Full Text
View/download PDF

3. Ruxolitinib - better prognostic impact in low-intermediate 1 risk score: evaluation of the 'rete ematologica pugliese' (REP) in primary and secondary myelofibrosis.

Author

Mazza P, Specchia G, Di Renzo N, Cascavilla N, Tarantini G, Capalbo SF, Urbano T, Albano F, Giovannni R, Falcone AP, Santeramo MT, Spinosa G, and Pisconti S

Subjects
Aged, Aged, 80 and over, Female, Humans, Male, Middle Aged, Myeloproliferative Disorders diagnosis, Myeloproliferative Disorders etiology, Nitriles, Primary Myelofibrosis diagnosis, Prognosis, Protein Kinase Inhibitors administration & dosage, Protein Kinase Inhibitors adverse effects, Pyrazoles administration & dosage, Pyrazoles adverse effects, Pyrimidines, Survival Analysis, Time Factors, Treatment Outcome, Myeloproliferative Disorders drug therapy, Myeloproliferative Disorders mortality, Primary Myelofibrosis drug therapy, Primary Myelofibrosis mortality, Protein Kinase Inhibitors therapeutic use, Pyrazoles therapeutic use
Abstract

We evaluated ruxolitinib in 65 patients with myelofibrosis according to age, sex, time of diagnosis, grade of fibrosis, prognostic score risk, Janus kinase (JAK) status, primary or secondary myelofibrosis, previous treatment, and dosage. Outcome measures were response rate, time to response, duration of response, and event-free survival and survival. Kaplan and Meier curves show a significant difference in event-free survival according to the prognostic score, in favor of patients with low int1 (p = 0.0009). The Cox stepwise model confirmed the result, the int2 high-risk score being the most powerful negative independent parameter (0.001), followed by JAK (0.008); other parameters, such as diagnosis more than 5 years earlier, grade III-IV fibrosis, and ruxolitinib dose have a negligible impact. Time to response was shorter (p = 0.001) in primary myelofibrosis. In conclusion, ruxolitinib is effective, with a better outcome in patients with a low-int1 risk score. This may suggest considering an earlier administration in the disease course.

Published
2017
Full Text
View/download PDF

4. Lenalidomide can induce long-term responses in patients with multiple myeloma relapsing after multiple chemotherapy lines, in particular after allogeneic transplant.

Author

Spina F, Montefusco V, Crippa C, Citro A, Sammassimo S, Olivero B, Gentili S, Galli M, Guglielmelli T, Rossi D, Falcone AP, Grasso M, Patriarca F, De Muro M, and Corradini P

Subjects
Adult, Aged, Aged, 80 and over, Cytogenetics, Dexamethasone administration & dosage, Dexamethasone therapeutic use, Humans, Immunoglobulin Isotypes immunology, Lenalidomide, Middle Aged, Multiple Myeloma drug therapy, Multiple Myeloma immunology, Multiple Myeloma mortality, Recurrence, Survival Analysis, Thalidomide therapeutic use, Time Factors, Transplantation, Homologous, Treatment Outcome, Antineoplastic Agents therapeutic use, Multiple Myeloma therapy, Stem Cell Transplantation, Thalidomide analogs & derivatives
Abstract

Evidence of long-term response to lenalidomide in heavily pretreated patients with multiple myeloma is lacking. This study sought to assess whether long-term responders exist, long-term responders' characteristics, and predictive factors of a long-term response. One hundred and four patients with multiple myeloma treated with lenalidomide and dexamethasone after ≥2 therapy lines (median, 3) were analyzed. Long-term response was defined as at least a partial response (≥PR) lasting ≥12 months. The overall response rate was 73%, and 80.3% of the responses were achieved within 5 months. The median response was 14.3 months. Patients evaluable for long-term response numbered 87, and a total of 47% were long-term responders. Compared to non-long-term responders, long-term responders had better overall survival, less light-chain multiple myeloma, and higher incidence of t(11;14). Previous allogeneic transplant (alloSCT) and the response quality predicted a long-term response. In conclusion, patients treated with lenalidomide can become long-term responders; alloSCT and response quality predict long-term response.

Published
2011
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results